All In Biotech

Drug Trial Radar · NCT03191162

Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project

Last checked: Nov 20, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Apr 21, 2017

Primary completion

Sep 21, 2020

Study completion Mar 16, 2021

Sponsor

Lead sponsor
Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2 clinical trial to evaluate the the efficacy of different benznidazole regimens (300mg/day for 60 days, 150mg/day for 60 days, and 400mg/day for 15 days) for the treatment of chronic Chagas disease in adult patients. The efficacy is assessed through the proportion of patients with negative parasitaemia measured by Polymerase Chain Reaction (PCR) during the first 12 months after starting treatment. The study will be performed in Spain, Brazil, Argentina and Colombia.

Conditions

  • Chagas Disease
  • Trypanosoma Cruzi Infection

Interventions

  • BenznidazoleDrug

    To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatmentTime frame: 12 months

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Instituto Nacional de Parasitología Dr. Mario Fatala Chaben (ANLIS)

    Buenos Aires, Argentina

  • Instituto de Cardiología de Corrientes Juana Francisca Cabral

    Corrientes, Argentina

  • Centro de Pesquisas René Rachou - Fundação Oswaldo Cruz. (FIOCRUZ)

    Belo Horizonte, Brazil

  • Hospital Universitário Clemente de Faria

    Montes Claros, Brazil

  • Fundación Cardioinfantil - Instituto de Cardiología

    Bogotá, Colombia

  • Centro Atencion y Diagnóstico de Enfermedades Infecciosas

    Bucaramanga, Colombia

  • Infectious Disease Department Vall d'Hebron Hospital

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.